FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2108952204> ?p ?o ?g. }

• W2108952204 endingPage "789" @default.
• W2108952204 startingPage "783" @default.
• W2108952204 abstract "1. The pharmacological profile of GR94839, a kappa-opioid agonist with limited access to the central nervous system, has been investigated. Its antinociceptive activity has been compared with that of GR103545, a centrally-penetrating kappa-agonist and ICI204448, the previously described peripherally-selective kappa-agonist. 2. GR94839 was a potent agonist in the rabbit vas deferens in vitro assay for kappa-opioid receptors (IC50: 1.4 +/- 0.3 nM; n = 6), but had limited activity at mu- or delta-opioid receptors. 3. In the mouse abdominal constriction test, GR94839 was 238 fold more potent when given i.c.v. (ED50: 0.008 (0.004-0.029) mg kg-1; n = 18) than when s.c. (ED50: 1.9 (0.7-3.1) mg kg-1; n = 30). In comparison, GR103545 was equipotent when given i.c.v. or s.c. 4. After intravenous administration, the maximum plasma to brain concentration-ratio attained by GR94839 was 18 compared with 2 for GR85571, a structurally-related kappa-agonist that is centrally-penetrating. 5. GR94839 inhibited the 2nd phase of the rat formalin response at doses 7 fold lower than those required to inhibit the 1st phase (ED50 vs 1st phase: 10.2 (6.7-17.1) mg kg-1, s.c.; ED50 vs 2nd phase: 1.4 (1.0-1.8) mg kg-1, s.c.; n = 18). GR103545 was equipotent against the two phases. 6. Intraplantar administration of the opioid antagonists, norbinaltorphimine (100 micrograms) or naltrexone (1 microgram), reversed the antinociceptive effect of systemic GR94839 (3 mg kg-1, s.c.) against the 2nd phase of the formalin response and intraplantar injection of GR94839 (30-100 micrograms) selectively inhibited the 2nd phase.7. GR94839 and IC1204448 reversed the hyperalgesia in the zymosan-inflamed rat paw at doses (ED50 GR94839: 2.0 (1.1-3.2) mg kg-', s.c.; ED50 IC1204448: 1.2 (0.8-1.7) mg kg-', s.c.), lower than those required to raise the noxious pressure threshold in the non-inflamed paw (EDSO GR94839: 16.4 (8.6-46.7) mg kg', s.c.; ED50 IC1204448: 68.0 (22.1-32000) mg kg', s.c.). GR103545 raised the noxious presure threshold in the inflamed and non-inflamed paws at the same doses.8. GR94839 was sedative in the rat rotarod test (ED50: 35 (12-245) mg kg-', s.c.) at doses higher than those required to inhibit the 2nd phase of the formalin response or reverse hyperalgesia in the zymosan-inflamed rat paw. The doses were comparable to those that inhibited the 1st phase of the formalin response and raised the noxious pressure threshold in the non-inflamed paw.9. The results suggest that GR94839 is a selective kappa-agonist which has antinociceptive activity against inflammatory pain at doses that produce limited central effects. These antinociceptive effects are probably mediated at peripheral opioid receptors." @default.
• W2108952204 created "2016-06-24" @default.
• W2108952204 creator A5016803135 @default.
• W2108952204 creator A5018522287 @default.
• W2108952204 creator A5021563044 @default.
• W2108952204 creator A5031904431 @default.
• W2108952204 creator A5062483078 @default.
• W2108952204 creator A5068907808 @default.
• W2108952204 creator A5070076669 @default.
• W2108952204 creator A5070639013 @default.
• W2108952204 creator A5079067389 @default.
• W2108952204 date "1992-08-01" @default.
• W2108952204 modified "2023-09-30" @default.
• W2108952204 title "GR94839, a κ-opioid agonist with limited access to the central nervous system, has antinociceptive activity" @default.
• W2108952204 cites W1932765998 @default.
• W2108952204 cites W1956678393 @default.
• W2108952204 cites W1967506194 @default.
• W2108952204 cites W1977704347 @default.
• W2108952204 cites W1994909080 @default.
• W2108952204 cites W1995099756 @default.
• W2108952204 cites W2001933690 @default.
• W2108952204 cites W2002887017 @default.
• W2108952204 cites W2011645297 @default.
• W2108952204 cites W2012094079 @default.
• W2108952204 cites W2018947654 @default.
• W2108952204 cites W2019249768 @default.
• W2108952204 cites W2020595768 @default.
• W2108952204 cites W2031573992 @default.
• W2108952204 cites W2031652422 @default.
• W2108952204 cites W2031765408 @default.
• W2108952204 cites W2041929412 @default.
• W2108952204 cites W2044131907 @default.
• W2108952204 cites W2046026171 @default.
• W2108952204 cites W2046524838 @default.
• W2108952204 cites W2053448648 @default.
• W2108952204 cites W2057384920 @default.
• W2108952204 cites W2064175661 @default.
• W2108952204 cites W2067681618 @default.
• W2108952204 cites W2073541816 @default.
• W2108952204 cites W2092996221 @default.
• W2108952204 cites W2165705027 @default.
• W2108952204 cites W2208417393 @default.
• W2108952204 doi "https://doi.org/10.1111/j.1476-5381.1992.tb14413.x" @default.
• W2108952204 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1907638" @default.
• W2108952204 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1327387" @default.
• W2108952204 hasPublicationYear "1992" @default.
• W2108952204 type Work @default.
• W2108952204 sameAs 2108952204 @default.
• W2108952204 citedByCount "40" @default.
• W2108952204 countsByYear W21089522042012 @default.
• W2108952204 countsByYear W21089522042013 @default.
• W2108952204 countsByYear W21089522042014 @default.
• W2108952204 countsByYear W21089522042015 @default.
• W2108952204 countsByYear W21089522042016 @default.
• W2108952204 countsByYear W21089522042017 @default.
• W2108952204 countsByYear W21089522042021 @default.
• W2108952204 countsByYear W21089522042022 @default.
• W2108952204 crossrefType "journal-article" @default.
• W2108952204 hasAuthorship W2108952204A5016803135 @default.
• W2108952204 hasAuthorship W2108952204A5018522287 @default.
• W2108952204 hasAuthorship W2108952204A5021563044 @default.
• W2108952204 hasAuthorship W2108952204A5031904431 @default.
• W2108952204 hasAuthorship W2108952204A5062483078 @default.
• W2108952204 hasAuthorship W2108952204A5068907808 @default.
• W2108952204 hasAuthorship W2108952204A5070076669 @default.
• W2108952204 hasAuthorship W2108952204A5070639013 @default.
• W2108952204 hasAuthorship W2108952204A5079067389 @default.
• W2108952204 hasBestOaLocation W21089522042 @default.
• W2108952204 hasConcept C126322002 @default.
• W2108952204 hasConcept C134018914 @default.
• W2108952204 hasConcept C15490471 @default.
• W2108952204 hasConcept C170493617 @default.
• W2108952204 hasConcept C184389661 @default.
• W2108952204 hasConcept C185592680 @default.
• W2108952204 hasConcept C2777972943 @default.
• W2108952204 hasConcept C2778938600 @default.
• W2108952204 hasConcept C2780820201 @default.
• W2108952204 hasConcept C2781063702 @default.
• W2108952204 hasConcept C42533223 @default.
• W2108952204 hasConcept C71924100 @default.
• W2108952204 hasConcept C98274493 @default.
• W2108952204 hasConceptScore W2108952204C126322002 @default.
• W2108952204 hasConceptScore W2108952204C134018914 @default.
• W2108952204 hasConceptScore W2108952204C15490471 @default.
• W2108952204 hasConceptScore W2108952204C170493617 @default.
• W2108952204 hasConceptScore W2108952204C184389661 @default.
• W2108952204 hasConceptScore W2108952204C185592680 @default.
• W2108952204 hasConceptScore W2108952204C2777972943 @default.
• W2108952204 hasConceptScore W2108952204C2778938600 @default.
• W2108952204 hasConceptScore W2108952204C2780820201 @default.
• W2108952204 hasConceptScore W2108952204C2781063702 @default.
• W2108952204 hasConceptScore W2108952204C42533223 @default.
• W2108952204 hasConceptScore W2108952204C71924100 @default.
• W2108952204 hasConceptScore W2108952204C98274493 @default.
• W2108952204 hasIssue "4" @default.
• W2108952204 hasLocation W21089522041 @default.
• W2108952204 hasLocation W21089522042 @default.
• W2108952204 hasLocation W21089522043 @default.

• next